Abstract 3963
Background
As an emerging technique, natural orifice specimen extraction surgery(NOSES) can avoid abdominal incision and improve cosmetic outcomes. However, the robotic application in NOSES for colorectal surgery is scarcely investigated.
Methods
For present study, all the colorectal specimen was transanally extracted. NOSES was classified into two types as following:1) Transanal eversion and extracorporal resection technique, which is mainly used for resection of lower and middle rectal cancer. 2) Intra-abdominal specimen resection and transanal extraction technique, which is mainly used for upper or middle rectal resection and sigmoid colectomy.
Results
Between October 2013 and March 2019, there were 155 patients with colorectal cancer undergoing robot-assisted NOSES. All the procedures were performed successfully without emergency requiring conversion to open surgery. The maximum diameter of rectal lesions was average 3.9±1.7cm, and distance to the lower edge of the lesion from the anal verge was measured to be 8.4±3.9 cm. The operating time for the entire procedures including rectal eversion, resection and anastomosis was 169.1±40.3 min, and blood loss during the procedures was 41.6±34.7 ml. Moreover, there were 16.1±5.7 lymph nodes dissected, and length to distal resection margin from tumor lower border was 1.7±0.9cm. Postoperatively, patients began first flatus and resumed fluid diet average 2.2±0.8 days and 1.3±0.3 days after surgery. Duration of postoperative hospital stay was median 7 days, while 12 patients developed anastomotic leakage, and both managed with conservative treatment. Median 15-month follow-up of all the 155 patients was performed to assess the middle/short term outcomes. During the follow-up period, there is no abdominal infection, pelvic abscess and other severe infectious complication for bacteriological outcome. For functional outcome, no dysuria, sexual function disorder and fecal incontinence were found among all the patients. Importantly, none of 155 patients were dead, and 8 patients were observed local recurrence or distant metastasis.
Conclusions
Robotic NOSES for colorectal cancer is safe and feasible. However, its long-term outcomes needs further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xu Jianmin, Colorectal Surgery Department, Zhongshan Hospital, Fudan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5124 - STAR_PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer.
Presenter: Hemant Kocher
Session: Poster Display session 2
Resources:
Abstract
5257 - Outcomes of First Line FOLFIRINOX (FFX) Versus Gemcitabine and Nab-Paclitaxel (GN) in Patients with Advanced Pancreatic Cancer: Multi-Institutional Canadian Sites Experience
Presenter: Neha Papneja
Session: Poster Display session 2
Resources:
Abstract
1166 - Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma
Presenter: Chaobin He
Session: Poster Display session 2
Resources:
Abstract
1169 - Association of combination of irreversible electroporation ablation and chemotherapy with outcomes of locally advanced pancreatic cancer: a large cohort study
Presenter: Chaobin He
Session: Poster Display session 2
Resources:
Abstract
1222 - Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer
Presenter: Yusuke Hashimoto
Session: Poster Display session 2
Resources:
Abstract
1698 - Multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer
Presenter: Masato Ozaka
Session: Poster Display session 2
Resources:
Abstract
2424 - Irinotecan Combined with Oxaliplatin and S1 in Patients with Metastatic Pancreatic Adenocarcinoma
Presenter: Keke Nie
Session: Poster Display session 2
Resources:
Abstract
2885 - Cancer-associated thrombosis in patients with pancreatic cancer and its correlation with plasma tissue factor level: A Japanese prospective cohort study
Presenter: Satoshi Kobayashi
Session: Poster Display session 2
Resources:
Abstract
3702 - A Phase I/Ib, multi-center trial of ARQ-761 (Beta-Lapachone) with gemcitabine/nab-Paclitaxel in patients with advanced pancreatic cancer
Presenter: Muhammad Beg
Session: Poster Display session 2
Resources:
Abstract
5185 - Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial
Presenter: Rocio Garcia-Carbonero
Session: Poster Display session 2
Resources:
Abstract